Ajinomoto Althea Adds High Potency Capabilities

Author(s)Pharmaceutical Technology Editors

Ajinomoto Althea opens manufacturing suites in new high potency and antibody drug conjugate commercial facility.

Ajinomoto Althea, Inc. announced on Sept. 19, 2017 that the company will open a GMP production suite in its newly constructed High Potency Products (HPP) commercial manufacturing facility in San Diego, CA. The facility is designed to develop, manufacture, test, and release HPPs including antibody drug conjugates, highly potent APIs, and other complex formulations of highly potent drugs.

The company currently offers process development and analytical services to clients from the facility and will be open for GMP bioconjugation and complex formulation in November 2017. Full manufacturing services, including high containment fill and finish, will commence in Q4 2018, as reported in a press statement on Sept. 19, 2017.

The company also announced that it secured its first manufacturing contract for the new facility.

Source: Ajinomoto Althea

Articles in this issue

over 8 years ago

Article

Finding a New Purpose for an Unproven Drug

over 8 years ago

Article

Demand for Efficiency Spurs Bioprocessing Innovation

over 8 years ago

Article

Fresenius Kabi Breaks Ground on $250-Million Facility Expansion

over 8 years ago

Article

UPS Reveals Supply Chain Security System

over 8 years ago

Article

Cambrex Adds Reactors to Facility in Sweden

over 8 years ago

Article

ADC Bio Invests $11 Million on Bioconjugation Facility

over 8 years ago

Article

Software Adds Data Integrity Functions

over 8 years ago

Article

Particle Analyzer Images Nanoparticles

over 8 years ago

Article

Global Effort to Stop Sale of Illegal Drugs Advances

over 8 years ago

Article

BASF Plans Amine Facility in Nanjing

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!